306 related articles for article (PubMed ID: 30277610)
1. Systems Thinking as a Framework for Analyzing Commercial Determinants of Health.
Knai C; Petticrew M; Mays N; Capewell S; Cassidy R; Cummins S; Eastmure E; Fafard P; Hawkins B; Jensen JD; Katikireddi SV; Mwatsama M; Orford J; Weishaar H
Milbank Q; 2018 Sep; 96(3):472-498. PubMed ID: 30277610
[TBL] [Abstract][Full Text] [Related]
2. A Systems Thinking Approach to Inform Coherent Policy Action for NCD Prevention Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
Milsom P; Smith R; Walls H
Int J Health Policy Manag; 2020 May; 9(5):212-214. PubMed ID: 32563223
[TBL] [Abstract][Full Text] [Related]
3. The
Lloyd-Williams F; Masters R; Hyseni L; Denny ES; O'Flaherty M; Capewell S
Int J Health Policy Manag; 2021 Oct; 10(10):638-646. PubMed ID: 32610821
[TBL] [Abstract][Full Text] [Related]
4. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure.
Buse K; Tanaka S; Hawkes S
Global Health; 2017 Jun; 13(1):34. PubMed ID: 28619031
[TBL] [Abstract][Full Text] [Related]
5. Engaging with the Private Sector for Noncommunicable Disease Prevention and Control: Is it Possible to Create "Shared Value?".
Collins TE; Akselrod S; Mahy L; Poznyak V; Berlina D; Hatefi A; Allen L
Ann Glob Health; 2023; 89(1):46. PubMed ID: 37425141
[TBL] [Abstract][Full Text] [Related]
6. Non-communicable disease governance in the era of the sustainable development goals: a qualitative analysis of food industry framing in WHO consultations.
Lauber K; Ralston R; Mialon M; Carriedo A; Gilmore AB
Global Health; 2020 Aug; 16(1):76. PubMed ID: 32847604
[TBL] [Abstract][Full Text] [Related]
7. Understanding Structure and Agency as Commercial Determinants of Health Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
Lee K; Crosbie E
Int J Health Policy Manag; 2020 Jul; 9(7):315-318. PubMed ID: 32613804
[TBL] [Abstract][Full Text] [Related]
8. Incorporating a structural approach to reducing the burden of non-communicable diseases.
Yang JS; Mamudu HM; John R
Global Health; 2018 Jul; 14(1):66. PubMed ID: 29980215
[TBL] [Abstract][Full Text] [Related]
9. Curbing the Rise of Noncommunicable Diseases in Uganda: Perspectives of Policy Actors.
Meghani A; Ssemugabo C; Pariyo G; Hyder AA; Rutebemberwa E; Gibson DG
Glob Health Sci Pract; 2021 Mar; 9(1):149-159. PubMed ID: 33795366
[TBL] [Abstract][Full Text] [Related]
10. On the Perils of Universal and Product-Led Thinking Comment on "How Neoliberalism Is Shaping the Supply of Unhealthy Commodities and What This Means for NCD Prevention".
Herrick C
Int J Health Policy Manag; 2020 May; 9(5):209-211. PubMed ID: 32563222
[TBL] [Abstract][Full Text] [Related]
11. An analysis of policy and funding priorities of global actors regarding noncommunicable disease in low- and middle-income countries.
Jailobaeva K; Falconer J; Loffreda G; Arakelyan S; Witter S; Ager A
Global Health; 2021 Jun; 17(1):68. PubMed ID: 34187499
[TBL] [Abstract][Full Text] [Related]
12. Identifying key factors for successful formulation and implementation of healthcare policies on non-communicable diseases: a multinational analysis.
Babaita AO; Jahan Y; Nakamura R; Moriyama M
Front Public Health; 2024; 12():1292176. PubMed ID: 38389939
[TBL] [Abstract][Full Text] [Related]
13. Corporate Political Activity: Taxonomies and Model of Corporate Influence on Public Policy.
Ulucanlar S; Lauber K; Fabbri A; Hawkins B; Mialon M; Hancock L; Tangcharoensathien V; Gilmore AB
Int J Health Policy Manag; 2023; 12():7292. PubMed ID: 37579378
[TBL] [Abstract][Full Text] [Related]
14. Corporate power and the international trade regime preventing progressive policy action on non-communicable diseases: a realist review.
Milsom P; Smith R; Baker P; Walls H
Health Policy Plan; 2021 May; 36(4):493-508. PubMed ID: 33276385
[TBL] [Abstract][Full Text] [Related]
15. The case for developing a cohesive systems approach to research across unhealthy commodity industries.
Knai C; Petticrew M; Capewell S; Cassidy R; Collin J; Cummins S; Eastmure E; Fafard P; Fitzgerald N; Gilmore AB; Hawkins B; Jensen JD; Katikireddi SV; Maani N; Mays N; Mwatsama M; Nakkash R; Orford JF; Rutter H; Savona N; van Schalkwyk MCI; Weishaar H
BMJ Glob Health; 2021 Feb; 6(2):. PubMed ID: 33593757
[TBL] [Abstract][Full Text] [Related]
16. Individual and community experience of rising burden of non-communicable diseases in two case districts of Nepal: a qualitative exploration.
Sharma SR; Matheson A; Lambrick D; Faulkner J; Lounsbury DW; Vaidya A; Page R
Glob Health Promot; 2022 Jun; 29(2):41-49. PubMed ID: 33845672
[TBL] [Abstract][Full Text] [Related]
17. A conceptual framework for investigating the impacts of international trade and investment agreements on noncommunicable disease risk factors.
Schram A; Ruckert A; VanDuzer JA; Friel S; Gleeson D; Thow AM; Stuckler D; Labonte R
Health Policy Plan; 2018 Jan; 33(1):123-136. PubMed ID: 29106574
[TBL] [Abstract][Full Text] [Related]
18. Assessing the association between Corporate Financial Influence and implementation of policies to tackle commercial determinants of non-communicable diseases: A cross-sectional analysis of 172 countries.
Allen LN; Wigley S; Holmer H
Soc Sci Med; 2022 Mar; 297():114825. PubMed ID: 35228150
[TBL] [Abstract][Full Text] [Related]
19. Building a Systems Map: Applying Systems Thinking to Unhealthy Commodity Industry Influence on Public Health Policy.
Bertscher A; Nobles J; Gilmore A; Bondy K; Akker AVD; Dance S; Bloomfield M; ZatoĊski M
Int J Health Policy Manag; 2024 Mar; ():. PubMed ID: 38618848
[TBL] [Abstract][Full Text] [Related]
20. Real-world data for precision public health of noncommunicable diseases: a scoping review.
Canfell OJ; Kodiyattu Z; Eakin E; Burton-Jones A; Wong I; Macaulay C; Sullivan C
BMC Public Health; 2022 Nov; 22(1):2166. PubMed ID: 36434553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
